300009 安科生物
已收盘 04-23 15:00:00
资讯
新帖
简况
百亿富豪的生长激素不灵了,355亿“东北药茅”神话破灭?
市场资讯 · 04-21 11:22
百亿富豪的生长激素不灵了,355亿“东北药茅”神话破灭?
安科生物收盘下跌1.11%,滚动市盈率18.95倍,总市值133.97亿元
金融界 · 04-16
安科生物收盘下跌1.11%,滚动市盈率18.95倍,总市值133.97亿元
安科生物:控股股东、实际控制人未减持公司股份并提前终止减持计划
美港电讯 · 02-24
安科生物:控股股东、实际控制人未减持公司股份并提前终止减持计划
安科生物:公司本次对维升药业的投资立足于长期战略发展规划
证券之星 · 02-21
安科生物:公司本次对维升药业的投资立足于长期战略发展规划
2月20日安科生物现1笔大宗交易 机构净买入201.35万元
证券之星 · 02-20
2月20日安科生物现1笔大宗交易 机构净买入201.35万元
安科生物2月20日现1笔大宗交易 成交金额201.35万元
新浪证券-红岸工作室 · 02-20
安科生物2月20日现1笔大宗交易 成交金额201.35万元
安科生物高级副总裁赵辉因个人资金需求再次减持,国际业务待突破
大消费之家 · 02-18
安科生物高级副总裁赵辉因个人资金需求再次减持,国际业务待突破
安科生物:2月14日高管赵辉减持股份合计20万股
证券之星 · 02-17
安科生物:2月14日高管赵辉减持股份合计20万股
安科生物(300009.SZ)董事赵辉完成减持 合计减持20万股
智通财经 · 02-17
安科生物(300009.SZ)董事赵辉完成减持 合计减持20万股
安科生物:公司暂无院士任职,设有与刘新垣院士团队合作的院士合作站
证券之星 · 02-14
安科生物:公司暂无院士任职,设有与刘新垣院士团队合作的院士合作站
安科生物涨5.89%,国金证券二日前给出“买入”评级
证券之星 · 02-14
安科生物涨5.89%,国金证券二日前给出“买入”评级
国金证券:给予安科生物买入评级
证券之星 · 02-12
国金证券:给予安科生物买入评级
安科生物(300009.SZ):拟作为基石投资者参与维升药业香港首次公开发行
格隆汇 · 02-11
安科生物(300009.SZ):拟作为基石投资者参与维升药业香港首次公开发行
安科生物最新公告:拟不超3100万美元参与认购维升药业香港首次公开发行股份
证券之星 · 02-11
安科生物最新公告:拟不超3100万美元参与认购维升药业香港首次公开发行股份
安科生物(300009.SZ)拟作为基石投资者参与维升药业H股IPO事项
智通财经 · 02-11
安科生物(300009.SZ)拟作为基石投资者参与维升药业H股IPO事项
安科生物:拟使用自有资金不超过3100万美元参与维升药业香港首次公开发行
美港电讯 · 02-11
安科生物:拟使用自有资金不超过3100万美元参与维升药业香港首次公开发行
安科生物(300009.SZ):人生长激素注射液新增适应症获批准
智通财经 · 02-06
安科生物(300009.SZ):人生长激素注射液新增适应症获批准
安科生物(300009.SZ)前三季度拟每10股派1元 1月17日除权除息
智通财经 · 01-10
安科生物(300009.SZ)前三季度拟每10股派1元 1月17日除权除息
加载更多
公司概况
公司名称:
安徽安科生物工程(集团)股份有限公司
所属行业:
医药制造业
上市日期:
2009-10-30
主营业务:
安徽安科生物工程(集团)股份有限公司的主营业务是基因工程药品、生物检测试剂的研发、生产、销售。公司的主要产品是人干扰素α2b注射液、注射用人干扰素α2b、人干扰素α2b栓剂、人干扰素α2b乳膏、人干扰素α2b滴眼液、注射用人生长激素、人生长激素注射液、注射用曲妥珠单抗、活血止痛膏、麝香镇痛膏、麝香壮骨膏、舒筋活络止痛膏、狗皮膏。公司入选2022年度江苏省专精特新中小企业、2022年获得江苏省省级企业技术中心认定。
发行价格:
17.00
{"stockData":{"symbol":"300009","market":"SZ","secType":"STK","nameCN":"安科生物","latestPrice":8.06,"timestamp":1745391819000,"preClose":8.09,"halted":0,"volume":9902287,"delay":0,"changeRate":-0.0037,"floatShares":1222000000,"shares":1673000000,"eps":0.3389,"marketStatus":"已收盘","change":-0.03,"latestTime":"04-23 15:00:00","open":8.09,"high":8.17,"low":8.03,"amount":79848200,"amplitude":0.0173,"askPrice":8.07,"askSize":456,"bidPrice":8.06,"bidSize":761,"shortable":0,"etf":0,"ttmEps":0.3389,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1745458200000},"marketStatusCode":5,"adr":0,"adjPreClose":8.09,"symbolType":"stock","openAndCloseTimeList":[[1745371800000,1745379000000],[1745384400000,1745391600000]],"highLimit":8.9,"lowLimit":7.28,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1672553658,"isCdr":false,"pbRate":3.28,"roa":"--","peRate":23.782827,"roe":"18.21%","epsLYR":0.42,"committee":0.177957,"marketValue":13481000000,"turnoverRate":0.0081,"status":1,"floatMarketCap":9847000000},"requestUrl":"/m/hq/s/300009","defaultTab":"news","newsList":[{"id":"2529808331","title":"百亿富豪的生长激素不灵了,355亿“东北药茅”神话破灭?","url":"https://stock-news.laohu8.com/highlight/detail?id=2529808331","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529808331?lang=zh_cn&edition=full","pubTime":"2025-04-21 19:22","pubTimestamp":1745234520,"startTime":"0","endTime":"0","summary":" 多元化能否助其再现增长神话? 2008年长春高新还是做房地产业务的,后来收购了金赛药业转型做生长激素,之后业绩和股价实现暴涨。被称为“东北药茅”的长春高新,在二股东金磊与前妻离婚,给了40亿股权“分手费”备受争议之后,4月20日,交出了近20年来首份年度收入同比下滑的成绩单。 年报及一季报公布之后,4月21日,长春高新盘中近乎跌停。市值较2021年巅峰时刻的2118亿元缩水了1763亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2025-04-21/doc-inetxsmq8547155.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1093756168.USD","IE00BZ1G4Q59.USD","LU2580892789.USD","300122","LU0154236417.USD","GSK.UK","LU1328615791.USD","BK0239","BK4588","688276","BK0046","BK4007","000661","688278","BK4585","BK0028","LU2148510915.USD","BK0042","GSK","BK0196","BK4599","LU1064130708.USD","BK0075","BK0057","BK0188","LU2580892862.HKD","BK0070","BK4532","LU1829250122.USD","BK0077","IE00BKVL7J92.USD","LU1064131003.USD","300009","LU1093756325.SGD","BK0060"],"gpt_icon":1},{"id":"2527934269","title":"安科生物收盘下跌1.11%,滚动市盈率18.95倍,总市值133.97亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2527934269","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527934269?lang=zh_cn&edition=full","pubTime":"2025-04-16 17:23","pubTimestamp":1744795426,"startTime":"0","endTime":"0","summary":"4月16日,安科生物今日收盘8.01元,下跌1.11%,滚动市盈率PE达到18.95倍,总市值133.97亿元。从行业市盈率排名来看,公司所处的生物制品行业市盈率平均40.40倍,行业中值35.49倍,安科生物排名第31位。截至2024年年报,共有176家机构持仓安科生物,其中基金175家、其他1家,合计持股数15378.40万股,持股市值13.29亿元。安徽安科生物工程(集团)股份有限公司的主营业务是基因工程药品、生物检测试剂的研发、生产、销售。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/16172349586313.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0042","BK0060","BK0070","BK0239","300009"],"gpt_icon":0},{"id":"2513474640","title":"安科生物:控股股东、实际控制人未减持公司股份并提前终止减持计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2513474640","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513474640?lang=zh_cn&edition=full","pubTime":"2025-02-24 18:36","pubTimestamp":1740393374,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0070","300009","BK1148","BK0060","09938","BK0042","BK0239"],"gpt_icon":0},{"id":"2513259854","title":"安科生物:公司本次对维升药业的投资立足于长期战略发展规划","url":"https://stock-news.laohu8.com/highlight/detail?id=2513259854","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513259854?lang=zh_cn&edition=full","pubTime":"2025-02-21 16:30","pubTimestamp":1740126626,"startTime":"0","endTime":"0","summary":"公司本次对维升药业的投资,立足于长期战略发展规划,着眼于医药产业未来发展机遇,体现了公司对维升药业未来发展潜力的认可,有利于优化公司资本运营效率,扩大资本市场影响力。公司与维升药业后续的合作规划,目前仍处于筹划阶段,相关信息请以公司披露的公告为准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025022100027041.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","300009","BK0070","BK0060","BK0239"],"gpt_icon":0},{"id":"2512641672","title":"2月20日安科生物现1笔大宗交易 机构净买入201.35万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512641672","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512641672?lang=zh_cn&edition=full","pubTime":"2025-02-20 17:03","pubTimestamp":1740042186,"startTime":"0","endTime":"0","summary":"证券之星消息,2月20日安科生物发生大宗交易,交易数据如下:大宗交易成交价格8.87元,成交22.7万股,成交金额201.35万元,买方营业部为机构专用,卖方营业部为中信证券股份有限公司上海分公司。近三个月该股共发生1笔大宗交易,合计成交2270.0手。该股在过去半年内已有共计601.25万股限售解禁股上市,占公司总股本的0.36%。截至2025年2月20日收盘,安科生物报收于8.87元,上涨0.45%,换手率2.14%,成交量26.17万手,成交额2.34亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025022000027691.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","300009","BK0239","BK0060","BK0042"],"gpt_icon":0},{"id":"2512735416","title":"安科生物2月20日现1笔大宗交易 成交金额201.35万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512735416","media":"新浪证券-红岸工作室","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512735416?lang=zh_cn&edition=full","pubTime":"2025-02-20 17:00","pubTimestamp":1740042000,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报,权威,专业,及时,全面,助您挖掘潜力主题机会! 2月20日,安科生物收涨0.45%,收盘价为8.87元,发生1笔大宗交易,合计成交量22.7万股,成交金额201.35万元。 第1笔成交价格为8.87元,成交22.70万股,成交金额201.35万元,溢价率为0.00%,买方营业部为机构专用,卖方营业部为中信证券股份有限公司上海分公司。 进一步统计,近3个月内该股累计发生1笔大宗交易,合计成交金额为201.35万元。该股近5个交易日累计上涨4.48%,主力资金合计净流入3871.57万元。\n\n\n\n海量资讯、精准解读,尽在新浪财经APP\n\n责任编辑:小浪快报","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/ggzz/2025-02-20/doc-inemcpfh2366734.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","BK0070","BK0060","300009","BK0042"],"gpt_icon":0},{"id":"2512182659","title":"安科生物高级副总裁赵辉因个人资金需求再次减持,国际业务待突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2512182659","media":"大消费之家","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512182659?lang=zh_cn&edition=full","pubTime":"2025-02-18 12:26","pubTimestamp":1739852760,"startTime":"0","endTime":"0","summary":"图片来源:安科生物公告赵辉多次减持股份,国际业务板块业绩待提升作为安科生物任职18年的董事,赵辉的职业生涯与企业发展似乎深度绑定。值得注意的是,赵辉几乎每次减持计划公布后,都会按照计划上限全额减持。赵辉的此次减持并非单独行动。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-02-18/doc-inekwqmn6823790.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["300009","BK0239","BK0060","BK0070","BK0042"],"gpt_icon":0},{"id":"2512140928","title":"安科生物:2月14日高管赵辉减持股份合计20万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2512140928","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512140928?lang=zh_cn&edition=full","pubTime":"2025-02-17 22:21","pubTimestamp":1739802065,"startTime":"0","endTime":"0","summary":"证券之星消息,根据2月17日市场公开信息、上市公司公告及交易所披露数据整理,安科生物最新董监高及相关人员股份变动情况:2025年2月14日公司董事,高管赵辉共减持公司股份20.0万股,占公司总股本为0.012%。安科生物近半年内的董监高及核心技术人员增减持详情如下:安科生物的高管列表及最新持股情况如下:融资融券数据显示该股近5日融资净流入421.48万,融资余额增加;融券净流入11.81万,融券余额增加。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025021700032951.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300009","BK0070","BK0239","BK0042","BK0060"],"gpt_icon":0},{"id":"2512941059","title":"安科生物(300009.SZ)董事赵辉完成减持 合计减持20万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2512941059","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512941059?lang=zh_cn&edition=full","pubTime":"2025-02-17 20:09","pubTimestamp":1739794175,"startTime":"0","endTime":"0","summary":"智通财经APP讯,安科生物(300009.SZ)公告,公司董事赵辉股份减持计划实施完成,截至2025年2月14日,赵辉减持计划已实施完成,合计减持公司股份20万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1250842.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300009","BK0070","BK0060","BK0042","BK0239"],"gpt_icon":0},{"id":"2511657955","title":"安科生物:公司暂无院士任职,设有与刘新垣院士团队合作的院士合作站","url":"https://stock-news.laohu8.com/highlight/detail?id=2511657955","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511657955?lang=zh_cn&edition=full","pubTime":"2025-02-14 17:30","pubTimestamp":1739525418,"startTime":"0","endTime":"0","summary":"证券之星消息,安科生物02月14日在投资者关系平台上答复投资者关心的问题。以院士工作站为依托,安科生物可在肿瘤精准医疗等领域拓展,延伸产业链,培育新的经济增长点。希望贵公司与市民携手防范空气污染,建设美丽家园安科生物董秘:您好,公司一直重视环保相关问题。公司废气主要涉及公辅设施。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025021400028126.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300009","BK0042","BK0060","BK0070","BK0239"],"gpt_icon":0},{"id":"2511659145","title":"安科生物涨5.89%,国金证券二日前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2511659145","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511659145?lang=zh_cn&edition=full","pubTime":"2025-02-14 16:23","pubTimestamp":1739521408,"startTime":"0","endTime":"0","summary":"今日安科生物涨5.89%,收盘报8.99元。2025年2月12日,国金证券研究员袁维发布了对安科生物的研报《拟基石投资维升药业,资源整合优势互补》,该研报对安科生物给出“买入”评级。2024-2026年公司对应EPS分别为0.47、0.63、0.73元,对应当前PE分别为18、15、12倍。维持“买入”评级。证券之星数据中心根据近三年发布的研报数据计算,该研报作者对此股的盈利预测准确度为69.28%。证券之星数据中心计算显示,对该股盈利预测较准的分析师团队为太平洋的盛丽华。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025021400025465.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300009"],"gpt_icon":0},{"id":"2510313709","title":"国金证券:给予安科生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2510313709","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510313709?lang=zh_cn&edition=full","pubTime":"2025-02-12 12:20","pubTimestamp":1739334031,"startTime":"0","endTime":"0","summary":"国金证券股份有限公司袁维近期对安科生物进行研究并发布了研究报告《拟基石投资维升药业,资源整合优势互补》,给予安科生物买入评级。 安科生物 事件简评 2025年2月11日,公司发布关于公司作为基石投资者参与维升药业香港首次公开发行的公告。维持“买入”评级。最新盈利预测明细如下:该股最近90天内共有1家机构给出评级,买入评级1家;过去90天内机构目标均价为10.14。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025021200017153.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300009"],"gpt_icon":0},{"id":"2510814382","title":"安科生物(300009.SZ):拟作为基石投资者参与维升药业香港首次公开发行","url":"https://stock-news.laohu8.com/highlight/detail?id=2510814382","media":"格隆汇","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510814382?lang=zh_cn&edition=full","pubTime":"2025-02-11 22:05","pubTimestamp":1739282722,"startTime":"0","endTime":"0","summary":"格隆汇2月11日丨安科生物(300009.SZ)公布,公司于2025年2月10日召开第八届董事会第十七次会议审议通过《关于全资子公司对外投资的议案》,同意公司拟使用自有资金不超过3100万美元(包括经纪佣金及征费等相关手续费)通过全资子公司安科生物(香港)有限公司(以下简称“安科生物(香港)”),作为基石投资者参与认购VISEN \nPharmaceuticals(中文名称“维升药业”,以下简称“维升药业”或“标的公司”)拟在香港联合交易所(以下简称“香港联交所”)发行的首次公开发行股份,并签署《基石投资协议》,具体持股比例将根据发行市值确定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/02/11220548091345.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["300009","BK0239","BK0060","BK0070","BK0042"],"gpt_icon":0},{"id":"2510384435","title":"安科生物最新公告:拟不超3100万美元参与认购维升药业香港首次公开发行股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2510384435","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510384435?lang=zh_cn&edition=full","pubTime":"2025-02-11 21:56","pubTimestamp":1739282212,"startTime":"0","endTime":"0","summary":"安科生物公告称,公司第八届董事会第十七次会议审议通过《关于全资子公司对外投资的议案》,同意使用自有资金不超过3100万美元作为基石投资者参与认购VISEN Pharmaceuticals(维升药业)拟在香港联合交易所发行的首次公开发行股份,并签署《基石投资协议》。本次投资旨在推动双方深度战略合作,提升公司的抗风险能力、核心竞争力和资本市场影响力。以上内容为证券之星据公开信息整理,由智能算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025021100037822.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","300009","BK0070","BK0042","BK0239"],"gpt_icon":0},{"id":"2510384410","title":"安科生物(300009.SZ)拟作为基石投资者参与维升药业H股IPO事项","url":"https://stock-news.laohu8.com/highlight/detail?id=2510384410","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510384410?lang=zh_cn&edition=full","pubTime":"2025-02-11 21:31","pubTimestamp":1739280686,"startTime":"0","endTime":"0","summary":"智通财经APP讯,安科生物 公告,公司董事会同意公司拟使用自有资金不超过3100万美元通过全资子公司安科生物(香港)有限公司,作为基石投资者参与认购维升药业拟在中国香港联合交易所发行的首次公开发行股份,并签署《基石投资协议》,具体持股比例将根据发行市值确定。此外,通过本次投资促进公司与维升药业建立密切的长期合作关系,推动双方在各自优势领域的深度战略合作,有助于实现资源整合和优势互补,充分发挥产业协同效应。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1248580.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300009","BK0070","BK0060","BK0042","BK0239"],"gpt_icon":0},{"id":"2510386646","title":"安科生物:拟使用自有资金不超过3100万美元参与维升药业香港首次公开发行","url":"https://stock-news.laohu8.com/highlight/detail?id=2510386646","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510386646?lang=zh_cn&edition=full","pubTime":"2025-02-11 21:16","pubTimestamp":1739279797,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0239","BK0060","300009","BK0042","BK0070"],"gpt_icon":0},{"id":"2509724467","title":"安科生物(300009.SZ):人生长激素注射液新增适应症获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2509724467","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509724467?lang=zh_cn&edition=full","pubTime":"2025-02-06 17:03","pubTimestamp":1738832633,"startTime":"0","endTime":"0","summary":"智通财经APP讯,安科生物(300009.SZ)公告,公司人生长激素注射液新增小于胎龄儿适应症的临床试验申请获得国家药品监督管理局批准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1246600.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0042","BK0060","BK0070","300009"],"gpt_icon":0},{"id":"2502852392","title":"安科生物(300009.SZ)前三季度拟每10股派1元 1月17日除权除息","url":"https://stock-news.laohu8.com/highlight/detail?id=2502852392","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2502852392?lang=zh_cn&edition=full","pubTime":"2025-01-10 20:03","pubTimestamp":1736510589,"startTime":"0","endTime":"0","summary":"智通财经APP讯,安科生物(300009.SZ)公告,公司2024年前三季度拟向全体股东每10股派1元人民币现金(含税),本次权益分派股权登记日为2025年1月16日,除权除息日为2025年1月17日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1236286.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300009","BK0060","BK0239","BK0042","BK0070"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1745395335942,"stockEarnings":[{"period":"1week","weight":-0.0012},{"period":"1month","weight":-0.068},{"period":"3month","weight":-0.0049},{"period":"6month","weight":-0.1251},{"period":"1year","weight":-0.1486},{"period":"ytd","weight":-0.0522}],"compareEarnings":[{"period":"1week","weight":0.0098},{"period":"1month","weight":-0.0193},{"period":"3month","weight":0.0268},{"period":"6month","weight":0.0059},{"period":"1year","weight":0.0838},{"period":"ytd","weight":-0.0155}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"安徽安科生物工程(集团)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"68123人(较上一季度增加1.42%)","perCapita":"17933股","listingDate":"2009-10-30","address":"安徽省合肥市蜀山区长江西路669号高新区海关路K-1","registeredCapital":"167255万元","survey":" 安徽安科生物工程(集团)股份有限公司的主营业务是基因工程药品、生物检测试剂的研发、生产、销售。公司的主要产品是人干扰素α2b注射液、注射用人干扰素α2b、人干扰素α2b栓剂、人干扰素α2b乳膏、人干扰素α2b滴眼液、注射用人生长激素、人生长激素注射液、注射用曲妥珠单抗、活血止痛膏、麝香镇痛膏、麝香壮骨膏、舒筋活络止痛膏、狗皮膏。公司入选2022年度江苏省专精特新中小企业、2022年获得江苏省省级企业技术中心认定。","listedPrice":17},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"安科生物(300009)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供安科生物(300009)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"安科生物,300009,安科生物股票,安科生物股票老虎,安科生物股票老虎国际,安科生物行情,安科生物股票行情,安科生物股价,安科生物股市,安科生物股票价格,安科生物股票交易,安科生物股票购买,安科生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"安科生物(300009)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供安科生物(300009)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}